Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

Acta Haematol. 2002;108(3):164-7. doi: 10.1159/000064700.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Acute Disease
  • Aged
  • Aminoglycosides*
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / immunology
  • Antigens, Differentiation, Myelomonocytic / immunology
  • Cytosine / adverse effects*
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use
  • Dioxolanes / adverse effects*
  • Dioxolanes / therapeutic use
  • Female
  • Gemtuzumab
  • Hepatic Veno-Occlusive Disease / etiology*
  • Hepatic Veno-Occlusive Disease / mortality
  • Humans
  • Leukemia, Myeloid / complications*
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / immunology
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / complications*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / immunology
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Dioxolanes
  • Sialic Acid Binding Ig-like Lectin 3
  • troxacitabine
  • Cytosine
  • Gemtuzumab